Bellicum reports third quarter 2020 financial results and provides operational update

Strategic focus on clinical gocar-t ® programs with plans to initiate phase 1/2 enrollment of bpx-601 in mcrpc and bpx-603 in her2+ solid tumors by end of year
BLCM Ratings Summary
BLCM Quant Ranking